Department of Hematology, The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
BMC Cancer. 2019 Mar 27;19(1):273. doi: 10.1186/s12885-019-5466-y.
Programmed cell death receptor 1 ligand 1 (PD-L1) expression in various tumors, including hematologic malignancies, has recently become a research topic of great interest. We performed a meta-analysis to evaluate the prognostic and clinicopathological value of PD-L1 expressed in tumor cells of patients with diffuse large B-cell lymphoma (DLBCL).
Relevant studies were identified from PubMed, EMBASE, Web of Science and the Cochrane Library. The hazard ratio (HR) and 95% confidence interval (95% CI) were used for analyzing survival outcomes, and the odds ratio (OR) was used for analyzing clinicopathological parameters.
Pooled results showed that tumor cell PD-L1 expression is associated with poor overall survival (OS) (HR = 2.128, 95% CI: 1.341-3.378, P = 0.001), the non-germinal center B-cell-like subtype (OR = 2.891, 95% CI: 2.087-4.003, P < 0.000), high international prognostic index score (3-5) (OR = 1.552, 95% CI: 1.111-2.169, P = 0.010), B symptoms (OR = 1.495, 95% Cl: 1.109-2.015, P = 0.008), positive MUM1 expression (OR = 3.365, 95% Cl: 1.578-7.175, P = 0.002) and negative BCL6 expression (OR = 0.414, 95% Cl: 0.217-0.792, P = 0.008). Sensitivity analysis showed that there was no publication bias among these studies.
Our meta-analysis supported the idea that tumor cell PD-L1 expression may represent a promising biomarker for predicting poor prognosis and is associated with adverse clinicopathologic features in DLBCL patients.
程序性死亡受体 1 配体 1（PD-L1）在包括血液恶性肿瘤在内的各种肿瘤中的表达，最近成为一个非常热门的研究课题。我们进行了一项荟萃分析，以评估肿瘤细胞中 PD-L1 表达在弥漫性大 B 细胞淋巴瘤（DLBCL）患者中的预后和临床病理价值。
从 PubMed、EMBASE、Web of Science 和 Cochrane Library 中确定相关研究。使用风险比（HR）和 95%置信区间（95%CI）分析生存结局，使用优势比（OR）分析临床病理参数。
汇总结果显示，肿瘤细胞 PD-L1 表达与总生存（OS）不良相关（HR=2.128，95%CI：1.341-3.378，P=0.001），非生发中心 B 细胞样亚型（OR=2.891，95%CI：2.087-4.003，P<0.000），高国际预后指数评分（3-5）（OR=1.552，95%CI：1.111-2.169，P=0.010），B 症状（OR=1.495，95%CI：1.109-2.015，P=0.008），MUM1 阳性表达（OR=3.365，95%CI：1.578-7.175，P=0.002）和 BCL6 阴性表达（OR=0.414，95%CI：0.217-0.792，P=0.008）。敏感性分析显示，这些研究之间没有发表偏倚。
我们的荟萃分析支持这样一种观点，即肿瘤细胞 PD-L1 表达可能代表一种有前途的生物标志物，可预测预后不良，并与 DLBCL 患者的不良临床病理特征相关。
